Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus

Authors: Rupert Langer, Marcus Feith, Joerg Rüdiger Siewert, Hans-Juergen Wester, Heinz Hoefler

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Glucose regulated proteins (GRPs) are main regulators of cellular homeostasis due to their role as molecular chaperones. Moreover, the functions of GRPs suggest that they also may play important roles in cancer biology. In this study we investigated the glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in a series of human esophageal adenocarcinomas to determine their implications in cancer progression and prognosis.

Methods

Formalin-fixed, paraffin-embedded tissues of primary resected esophageal (Barrett) adenocarcinomas (n = 137) and corresponding normal tissue were investigated. mRNA-gene expression levels of GRP78 and GRP94 were determined by quantitative real-time RT-PCR after mRNA extraction. Protein expression analysis was performed with immunohistochemical staining of the cases, assembled on a tissue micorarray. The results were correlated with pathologic features (pT, pN, G) and overall survival.

Results

GRP78 and GRP94 mRNA were expressed in all tumors. The relative gene expression of GRP78 was significantly higher in early cancers (pT1m and pT1sm) as compared to more advanced stages (pT2 and pT3) and normal tissue (p = 0.031). Highly differentiated tumors showed also higher GRP78 mRNA levels compared to moderate and low differentiated tumors (p = 0.035). In addition, patients with higher GRP78 levels tended to show a survival benefit (p = 0.07). GRP94 mRNA-levels showed no association to pathological features or clinical outcome.
GRP78 and GRP94 protein expression was detectable by immunohistochemistry in all tumors. There was a significant correlation between a strong GRP78 protein expression and early tumor stages (pT1m and pT1sm, p = 0.038). For GRP94 low to moderate protein expression was significantly associated with earlier tumor stage (p = 0.001) and less lymph node involvement (p = 0.036). Interestingly, the patients with combined strong GRP78 and GRP94 protein expression exclusively showed either early (pT1m or pT1sm) or advanced (pT3) tumor stages and no pT2 stage (p = 0.031).

Conclusion

We could demonstrate an association of GRP78 and GRP94 mRNA and protein expression with tumor stage and behaviour in esophageal adenocarcinomas. Increased expression of GRP78 may be responsible for controlling local tumor growth in early tumor stages, while high expression of GRP78 and GRP94 in advanced stages may be dependent from other factors like cellular stress reactions due to glucose deprivation, hypoxia or the hosts' immune response.
Appendix
Available only for authorised users
Literature
1.
Lee AS: The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001, 26 (8): 504-510. 10.1016/S0968-0004(01)01908-9.CrossRefPubMed
2.
Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS: The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit Rev Eukaryot Gene Expr. 1994, 4 (1): 1-18.CrossRefPubMed
3.
Dey A, Kessova IG, Cederbaum AI: Decreased protein and mRNA expression of ER stress proteins GRP78 and GRP94 in HepG2 cells over-expressing CYP2E1. Arch Biochem Biophys. 2006, 447 (2): 155-166. 10.1016/j.abb.2006.01.013.CrossRefPubMed
4.
Gazit G, Lu J, Lee AS: De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat. 1999, 54 (2): 135-146. 10.1023/A:1006102411439.CrossRefPubMed
5.
Miyake H, Hara I, Arakawa S, Kamidono S: Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J Cell Biochem. 2000, 77 (3): 396-408. 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5.CrossRefPubMed
6.
Qian Y, Harris ED, Zheng Y, Tiffany-Castiglioni E: Lead targets GRP78, a molecular chaperone, in C6 rat glioma cells. Toxicol Appl Pharmacol. 2000, 163 (3): 260-266. 10.1006/taap.1999.8878.CrossRefPubMed
7.
Sun S, Han J, Ralph WM, Chandrasekaran A, Liu K, Auborn KJ, Carter TH: Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones. 2004, 9 (1): 76-87.CrossRefPubMedPubMedCentral
8.
Melendez K, Wallen ES, Edwards BS, Mobarak CD, Bear DG, Moseley PL: Heat shock protein 70 and glycoprotein 96 are differentially expressed on the surface of malignant and nonmalignant breast cells. Cell Stress Chaperones. 2006, 11 (4): 334-342. 10.1379/CSC-187.1.CrossRefPubMedPubMedCentral
9.
Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, Patierno SR: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat. 2000, 59 (1): 15-26. 10.1023/A:1006332011207.CrossRefPubMed
10.
Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, Stevenson MA, Calderwood SK: Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones. 2005, 10 (1): 46-58. 10.1379/CSC-44R.1.CrossRefPubMedPubMedCentral
11.
Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M, Yasumoto K: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer. 2005, 49 (1): 55-62. 10.1016/j.lungcan.2004.12.011.CrossRefPubMed
12.
Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, Wang L, Wang S, Chen Y: Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev. 2005, 29 (6): 544-551. 10.1016/j.cdp.2005.09.010.CrossRefPubMed
13.
Wang XP, Qiu FR, Liu GZ, Chen RF: Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol. 2005, 11 (7): 1056-1059.CrossRefPubMedPubMedCentral
14.
Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y: Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J Gastroenterol. 2005, 11 (3): 429-432.CrossRefPubMedPubMedCentral
15.
Lee AS: GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007, 67 (8): 3496-3499. 10.1158/0008-5472.CAN-07-0325.CrossRefPubMed
16.
von Rahden BH, Stein HJ, Siewert JR: Barrett's esophagus and Barrett's carcinoma. Curr Oncol Rep. 2003, 5 (3): 203-209. 10.1007/s11912-003-0111-x.CrossRefPubMed
17.
Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric junction. Surg Oncol. 2000, 9 (1): 35-41. 10.1016/S0960-7404(00)00021-9.CrossRefPubMed
18.
Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000, 29 (4): 645-654. 10.1093/ije/29.4.645.CrossRefPubMed
19.
van Sandick JW, van Lanschot JJ, Tytgat GN, Offerhaus GJ, Obertop H: Barrett oesophagus and adenocarcinoma: an overview of epidemiologic, conceptual and clinical issues. Scand J Gastroenterol Suppl. 2001, 51-60. 10.1080/003655201753265451.
20.
Pera M: Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2000, 155: 1-14.CrossRefPubMed
21.
Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998, 85 (11): 1457-1459. 10.1046/j.1365-2168.1998.00940.x.CrossRefPubMed
22.
Sobin LH, Wittekind, Ch, eds.: TNM classification of malignant tumours. 2002, New York , John Wiley & Sons
23.
Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 2001, 158 (2): 419-429.CrossRefPubMedPubMedCentral
24.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3 (7): RESEARCH0034-10.1186/gb-2002-3-7-research0034.CrossRefPubMedPubMedCentral
25.
Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS: GRP78 as a Novel Predictor of Responsiveness to Chemotherapy in Breast Cancer. Cancer Res. 2006, 66 (16): 7849-7853. 10.1158/0008-5472.CAN-06-1660.CrossRefPubMed
26.
Mavropoulos JC, Fields TA, Pizzo SV: Chaperones and disease. N Engl J Med. 2005, 353 (26): 2821-2; author reply 2821-2. 10.1056/NEJMc052995.CrossRefPubMed
27.
Fu Y, Lee AS: Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther. 2006, 5 (7): 741-744.CrossRefPubMed
28.
Li J, Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006, 6 (1): 45-54. 10.2174/156652406775574523.CrossRefPubMed
29.
Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K: Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst. 2004, 96 (17): 1300-1310.CrossRefPubMed
30.
Park HR, Ryoo IJ, Choo SJ, Hwang JH, Kim JY, Cha MR, Shin-Ya K, Yoo ID: Glucose-deprived HT-29 human colon carcinoma cells are sensitive to verrucosidin as a GRP78 down-regulator. Toxicology. 2007, 229 (3): 253-261. 10.1016/j.tox.2006.11.049.CrossRefPubMed
31.
Chen X, Ding Y, Liu CG, Mikhail S, Yang CS: Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis. 2002, 23 (1): 123-130. 10.1093/carcin/23.1.123.CrossRefPubMed
32.
Neubauer H, Clare SE, Kurek R, Fehm T, Wallwiener D, Sotlar K, Nordheim A, Wozny W, Schwall GP, Poznanovic S, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Cahill MA: Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis. 2006, 27 (9): 1840-1852. 10.1002/elps.200500739.CrossRefPubMed
33.
Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Jung GH, Park CK: Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol. 2005, 11 (14): 2072-2079.CrossRefPubMedPubMedCentral
34.
Xing X, Lai M, Wang Y, Xu E, Huang Q: Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta. 2006, 364 (1-2): 308-315. 10.1016/j.cca.2005.07.016.CrossRefPubMed
35.
Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005, 10 (2): 86-103. 10.1379/CSC-99r.1.CrossRefPubMedPubMedCentral
36.
37.
Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS, Cote RJ: Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res. 2006, 12 (20 Pt 1): 5987-5993. 10.1158/1078-0432.CCR-06-0133.CrossRefPubMed
Metadata
Title
Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus
Authors
Rupert Langer
Marcus Feith
Joerg Rüdiger Siewert
Hans-Juergen Wester
Heinz Hoefler
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-70

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

Research article

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

Technical advance

Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR

Research article

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

Study protocol

Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling

Research article

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits